The pharmacokinetics of HIV protease inhibitor combinations.
about
Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding GroupOutcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort studyPharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.Initiating antiretrovirals during tuberculosis treatment: a drug safety review.Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection.Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimenThe management of HIV-1 protease inhibitor pharmacokinetic interactions.Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy.Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.Pharmacological management of cardiovascular conditions and diabetes in older adults with HIV infection.Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapyElectrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.HIV-associated neuromuscular weakness syndrome in Brazil: report of the two first cases.Analysis of possible drug-drug interactions between ritonavir and other antiretrovirals in a section of the private health care sector in South Africa.
P2860
Q27644661-A8A5B62F-08EE-4130-BA81-E38E8910C599Q34292138-38FECFFD-A8B0-4CD2-9354-2F5FC3C832BEQ34509848-F18EC899-4DB1-47B8-B01A-A0D9E1F3D2A1Q35043048-A5B4AD3E-DD39-487E-BBB6-C0A094F43327Q35061983-2A143980-D8FB-4A6D-9795-7984AA36E298Q35715660-28EA9388-EF14-461F-AA5A-781C0442C7BEQ35758844-A373CC8D-E69D-4AC2-9985-E7DC5063485DQ36154861-9B9B9B2A-DAA7-4B55-9796-B9BEB907AB50Q36235489-76F48473-F7EE-4433-9CE9-7F5502CAAF91Q36723780-0133529C-22EC-4BE4-A017-C1322E9B0BB7Q38172305-BAA19A49-B997-419E-8C7F-7EF2BBB16F95Q41842301-4E6FBD9A-9190-4152-83A4-4F21129D1FA0Q42085839-63EF6FB9-082A-4508-8671-50FAFEA512EBQ43244207-E3566BAA-40F0-4D85-A881-07D79A4A4C43Q46938579-A01BD844-F5F5-4FC9-85AB-911A76FC3A8AQ55208876-7B8F2892-31BB-4293-A8BA-06E3D9E6E814
P2860
The pharmacokinetics of HIV protease inhibitor combinations.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The pharmacokinetics of HIV protease inhibitor combinations.
@ast
The pharmacokinetics of HIV protease inhibitor combinations.
@en
type
label
The pharmacokinetics of HIV protease inhibitor combinations.
@ast
The pharmacokinetics of HIV protease inhibitor combinations.
@en
prefLabel
The pharmacokinetics of HIV protease inhibitor combinations.
@ast
The pharmacokinetics of HIV protease inhibitor combinations.
@en
P2093
P1476
The pharmacokinetics of HIV protease inhibitor combinations.
@en
P2093
Anton Pozniak
Desmond Maitland
Marta Boffito
Yohan Samarasinghe
P356
10.1097/00001432-200502000-00002
P577
2005-02-01T00:00:00Z